Informações:
Falhas:
ID
22477
Descrição
APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire); ODM derived from: https://clinicaltrials.gov/show/NCT00523315
Link
https://clinicaltrials.gov/show/NCT00523315
Palavras-chave
Versões (1)
- 05/06/2017 05/06/2017 -
Transferido a
5 de junho de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00523315
Eligibility Breast Cancer NCT00523315
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00523315
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
provision of written informed consent
boolean
C0021430 (UMLS CUI [1])
ID.2
Item
patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice
boolean
C1880501 (UMLS CUI [1,1])
C2986665 (UMLS CUI [1,2])
C2986665 (UMLS CUI [1,2])
ID.3
Item
histologically or cytologically proven to be hr+(er or pr +)
boolean
C2247599 (UMLS CUI [1])
ID.4
Item
postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline):
boolean
C0232970 (UMLS CUI [1,1])
C0043210 (UMLS CUI [1,2])
C0043210 (UMLS CUI [1,2])
ID.5
Item
age >= 50 years
boolean
C0001779 (UMLS CUI [1])
ID.6
Item
age < 50 years with amenorrhoea > 12 months and an intact uterus
boolean
C0001779 (UMLS CUI [1,1])
C0002453 (UMLS CUI [1,2])
C0002453 (UMLS CUI [1,2])
ID.7
Item
fsh levels within postmenopausal range (over 30-40 iu/ml), or
boolean
C0202022 (UMLS CUI [1])
ID.8
Item
having undergone a bilateral oophorectomy.
boolean
C0278321 (UMLS CUI [1])
ID.9
Item
no other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
boolean
C1880501 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,2])
ID.10
Item
recurrence of breast cancer
boolean
C0006142 (UMLS CUI [1,1])
C1458156 (UMLS CUI [1,2])
C1458156 (UMLS CUI [1,2])
ID.11
Item
known hypersensitivity to aromatase inhibitor or to any of the excipients
boolean
C3548805 (UMLS CUI [1])
ID.12
Item
any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol
boolean
C0877248 (UMLS CUI [1])
ID.13
Item
previous inclusion in the present study
boolean
C1512693 (UMLS CUI [1])
ID.14
Item
participation in a clinical study during the last 30 days
boolean
C0008976 (UMLS CUI [1])